[1]郑时玉,郭亚男.c-Met及MACC1在甲状腺乳头状癌中的表达及临床意义[J].医学信息官方网站,2022,35(15):36-38,45.[doi:10.3969/j.issn.1006-1959.2022.15.007]
 ZHENG Shi-yu,GUO Ya-nan.Expression and Clinical Significance of c-Met and MACC1 in Papillary Thyroid Carcinoma[J].Medical Information,2022,35(15):36-38,45.[doi:10.3969/j.issn.1006-1959.2022.15.007]
点击复制

c-Met及MACC1在甲状腺乳头状癌中的表达及临床意义()
分享到:

《医学信息》官方网站[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年15期
页码:
36-38,45
栏目:
论著
出版日期:
2022-08-01

文章信息/Info

Title:
Expression and Clinical Significance of c-Met and MACC1 in Papillary Thyroid Carcinoma
文章编号:
1006-1959(2022)15-0036-04
作者:
郑时玉郭亚男
(宁波市临床病理诊断中心组织病理科,浙江 宁波 315000)
Author(s):
ZHENG Shi-yuGUO Ya-nan
(Department of Histopathology,Ningbo Diagnostic Pathology Center,Ningbo 315000,Zhejiang,China)
关键词:
甲状腺乳头状癌c-MetMACC1免疫组织化学
Keywords:
Papillary thyroid carcinomac-MetMACC1Immunohistochemistry
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2022.15.007
文献标志码:
A
摘要:
目的 探讨肝细胞生长因子受体(c-Met)与结肠癌转移相关基因(MACC1)在甲状腺乳头状癌中的表达,及其与甲状腺乳头状癌临床病理特征的关系。方法 采用免疫组织化学染色法检测60例甲状腺乳头状癌组织及30例良性甲状腺组织(甲状腺腺瘤15例,结节性甲状腺肿15例)中c-Met及MACC1的表达情况,并结合临床病理特征进行相关分析。结果 c-Met及 MACC1蛋白在甲状腺乳头状癌中的阳性表达率均高于良性甲状腺疾病,差异有统计学意义(P<0.05);Spearman相关性检验结果表明c-Met与 MACC1蛋白在甲状腺乳头状癌中的表达呈正相关(r=0.394,P<0.05);MACC1蛋白在有无淋巴结转移的甲状腺乳头状癌的阳性表达率比较,差异有统计学意义(P<0.05);而不同年龄、性别、肿块大小c-Met蛋白及MACC1蛋白阳性表达率比较,差异无统计学意义(P>0.05);c-Met蛋白在有无淋巴结转移的甲状腺乳头状癌的阳性表达率比较,差异无统计学意义(P>0.05)。结论 MACC1及c-Met蛋白可能参与了甲状腺乳头状癌的发生发展过程,并可能对甲状腺乳头状癌的诊断及靶向治疗提供思路。
Abstract:
Objective To investigate the expression of c-metprotoncogene (c-Met) and colon cancer metastasis-related gene (MACC1) in papillary thyroid carcinoma and its relationship with clinicopathological features of papillary thyroid carcinoma.Methods Immunohistochemical staining was used to detect the expression of c-Met and MACC1 in 60 cases of papillary thyroid carcinoma and 30 cases of benign thyroid tissues ( 15 cases of thyroid adenoma and 15 cases of nodular goiter), and correlation analysis was carried out combined with clinical pathological features.Results The positive expression rates of c-Met and MACC1 protein in papillary thyroid carcinoma were higher than those in benign thyroid diseases, and the difference was statistically significant (P<0.05). Spearman correlation test showed that the expression of c-Met and MACC1 protein in papillary thyroid carcinoma was positively correlated (r=0.394, P<0.05). The positive expression rate of MACC1 protein in papillary thyroid carcinoma with or without lymph node metastasis was statistically significant (P<0.05); while there was no significant difference in the positive expression rate of c-Met protein and MACC1 protein in different age, gender, tumor size (P>0.05). There was no significant difference in the positive expression rate of c-Met protein in papillary thyroid carcinoma with or without lymph node metastasis (P>0.05).Conclusion MACC1 and c-Met protein may be involved in the occurrence and development of papillary thyroid carcinoma, and may provide ideas for the diagnosis and targeted therapy of papillary thyroid carcinoma.

参考文献/References:

[1]Ulrike S,Wolfgang W,Franziska A,et al.MACC1, a newly identified key regulator of HGF-MET signaling,predicts colon cancer metastasis[J].Nat Med,2009,15(1):59-67.[2]Tong GL,Cheng B,Li JZ,et al.MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/Mtor pathway in gastric cancer cells[J].Cancer Med,2019,8(16):7044-7054.[3]Shi W,Song J,Wang W,et al.MACC 1 antibody target therapy suppresses growth and migration of non small cell lung cancer[J].Mol Med Rep,2017,16(5):7329-7336.[4]Dahlmann M,Werner R,Kortüm B,et al.Restoring Treatment Response in Colorectal Cancer Cells by Targeting MACC1-Dependent ABCB1 Expression in Combination Therapy[J].Front Oncol,2020,10:599.[5]Makino T,Orita Y,Gion Y,et al.MACC1 expression is an indicator of recurrence in early-stage glottis cancer[J].Jpn J Clin Oncol,2020,50(4):392-398.[6]Wen J,Xie Y,Zhang Y,et al.MACC1 contributes to the development of Osteosarcoma through regulation of the HGF/c-Met pathway and microtubule stability[J].Front Cell Dev Biol,2020,8:825.[7]Trovato M,Campennì A,Giovinazzo S,et al.Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target[J].Biomarker Insights,2017,12:1-8.[8]Tong H,Liu X,Li T,et al.MACC1-AS1 promotes hepatocellular carcinoma cell invasion and proliferation by regulating PAX8[J].Aging (Albany NY),2020,12(1):70-79.[9]Czerniak B,Olszewska-SloninaD,Cwynar A.S100A4, MACC-1, REG-4-promising biomarkers of metastasis in cancers[J].Wiad Lek,2017,70(3):604-607.[10]Li Z,Yanfang W,Li J,et al.Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer[J].Cancer Lett,2018,432:237-250.[11]Wang L,Zhou R,Zhao Y.MACC-1 Promotes Endothelium-Dependent Angiogenesis in Gastric Cancer by Activating TWIST1/VEGF-A Signal Pathway[J].PLoS One,2016,9:11.[12]Peng T,Li Z,Li D,et al.MACC1 promotes angiogenesis in cholangiocarcinoma by upregulating VEGFA[J].Onco Targets Ther,2019,12:1893-1903.[13]Zheng D,Che D,Lin F,et al.LncRNA MACC1-AS1/MACC1 enhances the progression of glioma via regulating metabolic plasticity[J].Cell Cycle,2020,19(18):2286-2297.[14]Budczies J,Kluck K,Walther W,et al.Decoding and targeting the molecular basis of MACC1-driven metastatic spread: Lessons from big data mining and clinical-experimental approaches[J].Semin Cancer Biol,2020,60:365-379.[15]Hohmann T,Hohmann U,Kolbe MR,et al.MACC1 driven alterations in cellular biomechanics facilitate cell motility in glioblastoma[J].Cell Commun Signal,2020,18(1):85.[16]Lin CH,Hsieh MJ,Lee HL.Effects of MACC1 polymorphisms on hepatocellular carcinoma development and clinical characteristics[J].J Cancer,2020,11(6):1641-1647.[17]王瑾,韩若凌,张凤娟.Gelectin-3、c-met、HBME-1及CK19表达结合超声对于甲状腺癌淋巴结转移及预后的评估价值[J].中华超声影像学杂志,2018,27(11):963-967.[18]王艳,王倩,赵永明,等.c-Met在甲状腺癌中的表达及其临床病理意义[J].浙江医学,2015,37(3):208-210.[19]马泽忠,刘建,李自力.甲状腺乳头状癌患者血清MACC1及糖类抗原的表达及预后[J].热带医学杂志,2019,5(8):987-990.[20]Ahmed M,Aslam M.Serum MACC-1:a new biomarker for breast cancer[J].Oncotarget,2020,11(48):4521-4526.

相似文献/References:

[1]李 想,孙春雷,张 懿,等.无充气腋窝入路腔镜手术治疗甲状腺乳头状癌的疗效研究[J].医学信息官方网站,2021,34(04):115.[doi:10.3969/j.issn.1006-1959.2021.04.030]
 LI Xiang,SUN Chun-lei,ZHANG Yi,et al.Study on the Curative Effect of Laparoscopic Surgery Non-inflated Axillary Approach in the Treatment of Papillary Thyroid Carcinoma[J].Medical Information,2021,34(15):115.[doi:10.3969/j.issn.1006-1959.2021.04.030]
[2]刘 彻,艾力·赛丁,苏鹏程.甲状腺乳头状癌颈部淋巴结转移特点及相关危险因素分析[J].医学信息官方网站,2019,32(23):70.[doi:10.3969/j.issn.1006-1959.2019.23.019]
 LIU Che,Aili·SaiDing,SU Peng-cheng.Analysis of Cervical Lymph Node Metastasis and Related Risk Factors in Papillary Thyroid Carcinoma[J].Medical Information,2019,32(15):70.[doi:10.3969/j.issn.1006-1959.2019.23.019]
[3]唐嘉晨,郝玲玲,秦晓茹,等.全腔镜下甲状腺乳头状癌并发症Meta分析[J].医学信息官方网站,2021,34(04):78.[doi:10.3969/j.issn.1006-1959.2021.04.021]
 TANG Jia-chen,HAO Ling-ling,QIN Xiao-ru,et al.Meta-analysis of Complications of Papillary Thyroid Carcinoma Under Full Laparoscopic Surgery[J].Medical Information,2021,34(15):78.[doi:10.3969/j.issn.1006-1959.2021.04.021]
[4]范雪峰,王伦锋,余招焱,等.左侧及右侧中央区淋巴结清扫在甲状腺乳头状癌术中的应用[J].医学信息官方网站,2021,34(09):5.[doi:10.3969/j.issn.1006-1959.2021.09.002]
 FAN Xue-feng,WANG Lun-feng,YU Zhao-yan,et al.Left and Right Central Lymph Node Dissection in the Operation of Papillary Thyroid Carcinoma[J].Medical Information,2021,34(15):5.[doi:10.3969/j.issn.1006-1959.2021.09.002]
[5]徐海燕,潘景润,宫希军,等.CT增强联合甲状腺球蛋白及抗体在甲状腺乳头状癌颈部淋巴结转移中的预测价值[J].医学信息官方网站,2021,34(20):119.[doi:10.3969/j.issn.1006-1959.2021.20.030]
 XU Hai-yan,PAN Jing-run,GONG Xi-jun,et al.The Value of CT Enhancement Combined with Thyroglobulin and Antibody in PredictingCervical Lymph Node Metastasis of Papillary Thyroid Carcinoma[J].Medical Information,2021,34(15):119.[doi:10.3969/j.issn.1006-1959.2021.20.030]
[6]李佳楠,陈春悠.STAT3、NCK1和VEGF在甲状腺乳头状癌中的表达及临床意义[J].医学信息官方网站,2022,35(05):94.[doi:10.3969/j.issn.1006-1959.2022.05.023]
 LI Jia-nan,CHEN Chun-you.Expression of STAT3, NCK1 and VEGF in Papillary Thyroid Carcinoma and its Clinical Significance[J].Medical Information,2022,35(15):94.[doi:10.3969/j.issn.1006-1959.2022.05.023]
[7]李雪松,苏新良,陶冬梅.术前诊断不明确的甲状腺乳头状癌的风险分析[J].医学信息官方网站,2024,37(04):119.[doi:10.3969/j.issn.1006-1959.2024.04.021]
 LI Xue-song,SU Xin-liang,TAO Dong-mei.Risk Analysis of Papillary Thyroid Carcinoma with Undefinable Preoperative Diagnosis[J].Medical Information,2024,37(15):119.[doi:10.3969/j.issn.1006-1959.2024.04.021]

更新日期/Last Update: 1900-01-01